Eupraxia Pharma Reports Positive Phase Trial Data for EP-104GI
On August 13, Eupraxia Pharmaceuticals (NASDAQ:EPRX) released encouraging data from its ongoing RESOLVE trial of lead drug candidate EP-104GI. The treatment showed significant improvement in patients with odynophagia and dysphagia—conditions involving painful or difficult swallowing—with the highest-dose cohorts experiencing a marked reduction in symptoms over 24 to 52 weeks. The data also indicated consistent improvements across multiple measures, including endoscopic findings and tissue biopsies. Eupraxia reported strong financials as of June 30, with $52.4 million in cash and $81.2 million in short-term investments, providing funding through the second half of 2028. However, these results come from an open-label portion of the trial; a larger randomized Phase 2b study is still underway. The company faces challenges including rising costs due to expanded trials and organizational changes such as leadership shifts and operational relocations. Despite this, institutional interest in Eupraxia has increased, with more hedge funds holding positions recently.
Topics: drug development gastrointestinal disorders pharmaceuticals